BioCentury
ARTICLE | Company News

United Therapeutics sales and marketing update

July 25, 2016 7:00 AM UTC

The U.K.’s NICE issued final draft guidance recommending against Unituxin dinutuximab from United Therapeutics to treat high-risk neuroblastoma in combination with GM-CSF, IL-2 and isotretinoin in pa...